Digitalis glycosides.
The digitalis glycosides are potent cardiovascular drugs with a low therapeutic index and a high incidence of iatrogenic complications. Digoxin is the most commonly used preparation. Common indications include rate control in atrial fibrillation, as well as the treatment of other atrial tachyarrhythmias, and low-output congestive heart failure. Digitalis is contraindicated in idiopathic hypertrophic subaortic stenosis (unless atrial fibrillation is present) and in some patients with Wolff-Parkinson-White syndrome.
D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001682:Biological Availability; D004071:Digitalis Glycosides / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004074:Digitoxin / Q000378:metabolism / Q000494:pharmacology; D004077:Digoxin / Q000378:metabolism / Q000494:pharmacology; D004334:Drug Administration Schedule; D004347:Drug Interactions; D006321:Heart / Q000187:drug effects; D006801:Humans; D007473:Ion Channels / Q000187:drug effects; D013268:Stimulation, Chemical
D004071:Digitalis Glycosides; D007473:Ion Channels; D004077:Digoxin; D004074:Digitoxin